Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Keating

Showing results (61-70 of 341) with videos related to

Pageof 35
Sort By:
Leukemia & Lymphoma|April 12, 2003
Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemiaGiovanni D'Arena, Nicola Di Renzo, Maura Brugiatelli, et al.
Blood|March 8, 2012
Risk categories and refractory CLL in the era of chemoimmunotherapyThorsten Zenz, John G Gribben, Michael Hallek, et al.
Cancer|April 2, 2005
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analogStefan Faderl, Varsha Gandhi, Michael J Keating, et al.
Oncotarget|May 26, 2016
Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimeticKumudha Balakrishnan, Min Fu, Francesco Onida, et al.
Hematology (Amsterdam, Netherlands)|December 29, 2004
Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cellsCarlos E Bueso-Ramos, Alessandra Ferrajoli, L Jeffrey Medeiros, et al.
Oncotarget|February 11, 2017
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cellsPrexy Modi, Kumudha Balakrishnan, Qingshan Yang, et al.
Cancer|May 13, 2004
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndromeApostolia-Maria Tsimberidou, James L Murray, Susan O'Brien, et al.
Leukemia & Lymphoma|April 10, 2008
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicatorsZhifeng Yu, Baohua Sun, Hagop M Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practiceDavid S Sanford, William G Wierda, Jan A Burger, et al.
Blood|January 10, 2015
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemiaBetty Lamothe, Fabiola Cervantes-Gomez, Mariela Sivina, et al.
Pageof 35

Showing results (61-70 of 341) with videos related to

Sort By:
Pageof 35
Leukemia & Lymphoma|April 12, 2003
Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemiaGiovanni D'Arena, Nicola Di Renzo, Maura Brugiatelli, et al.
Blood|March 8, 2012
Risk categories and refractory CLL in the era of chemoimmunotherapyThorsten Zenz, John G Gribben, Michael Hallek, et al.
Cancer|April 2, 2005
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analogStefan Faderl, Varsha Gandhi, Michael J Keating, et al.
Oncotarget|May 26, 2016
Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimeticKumudha Balakrishnan, Min Fu, Francesco Onida, et al.
Hematology (Amsterdam, Netherlands)|December 29, 2004
Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cellsCarlos E Bueso-Ramos, Alessandra Ferrajoli, L Jeffrey Medeiros, et al.
Oncotarget|February 11, 2017
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cellsPrexy Modi, Kumudha Balakrishnan, Qingshan Yang, et al.
Cancer|May 13, 2004
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndromeApostolia-Maria Tsimberidou, James L Murray, Susan O'Brien, et al.
Leukemia & Lymphoma|April 10, 2008
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicatorsZhifeng Yu, Baohua Sun, Hagop M Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practiceDavid S Sanford, William G Wierda, Jan A Burger, et al.
Blood|January 10, 2015
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemiaBetty Lamothe, Fabiola Cervantes-Gomez, Mariela Sivina, et al.
Pageof 35